T Masaoka, Y Hasegawa, T Ueda, T Takubo, H Shibata. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Acute DiseaseAdolescentAdultAminobiphenyl Compounds/therapeutic useAntineoplastic Agents/therapeutic useAsparaginase/therapeutic useBone Marrow/pathologyCell Survival/drug effectsChildChild, PreschoolCytarabine/analogs & derivativesCytarabine/therapeutic useDaunorubicin/therapeutic useDrug Therapy, CombinationFemaleHumansLeukemia/bloodLeukemia/drug therapyLeukemia/pathologyLeukocyte CountMaleMercaptopurine/therapeutic useMesylates/therapeutic useMethotrexate/therapeutic useMiddle AgedNeutrophilsPrednisolone/therapeutic useTime FactorsZinostatin/therapeutic use
Substances： See more » Aminobiphenyl CompoundsAntineoplastic AgentsMesylatesCytarabineZinostatinPrednisoloneMercaptopurineAsparaginaseMethotrexateDaunorubicin
Year: 1976 PMID： 177291 DOI： 10.1016/0014-2964(76)90218-8
Source DB: PubMed Journal: Eur J Cancer ISSN： 0014-2964 Impact factor: 9.162